Once-daily treatment with Gain Therapeutics‘ GT-02287 rescued motor function and cognitive performance in a mouse model of Parkinson’s disease associated with mutations in the GBA1 gene. “These data further confirm our conviction that GT-02287 can slow or stop progression of Parkinson’s disease and given the cognitive decline observed…
Six genetic variants associated with mortality and motor progression have been discovered in people with Parkinson’s disease. These newly detected genetic factors that influenced disease progression were largely different from those that increased Parkinson’s risk, researchers found. “This work will help us to better understand the biology of [Parkinson’s]…
Dosing has begun in a Phase 1 clinical trial evaluating the safety and efficacy of IRL757, an oral candidate for apathy treatment in people with Parkinson’s disease and other neurological conditions. Irlab Therapeutics, the therapy’s developer, recently announced the trial’s launch following approval by the Swedish Medical…
The U.S. Senate has joined the House of Representatives in approving The National Plan to End Parkinson’s Act, the first piece of federal legislation dedicated to ending Parkinson’s disease. Celebrated by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the bill now will be sent to…
Deficits in emotional processing, rather than impaired ability to simulate facial expressions, likely explain problems Parkinson’s disease patients encounter when trying to recognize emotions on human faces, a study suggests. Researchers asked patients and healthy individuals to recognize different, non-emotional facial expressions on avatars, either static or moving. No…
Potential environmentally-driven alterations in certain epigenetic marks — DNA modifications that control gene activity — were detected in the blood of people with newly diagnosed, treatment-naïve, sporadic Parkinson’s disease, a study revealed. These epigenetic marks were linked with cellular processes driving ongoing neurodegeneration that underlies Parkinson’s, and changed over…
Six months of daily tavapadon, as an oral add-on therapy to standard levodopa, significantly increased on time without troublesome dyskinesia, or involuntary body movements, in people in the late stages of Parkinson’s disease, according to top-line data from a Phase 3 study. Data from the trial, dubbed…
Sage Therapeutics’ dalzanemdor, formerly known as SAGE-718, an investigational oral medication for mild cognitive impairment (MCI) due to Parkinson’s disease, has failed to outperform a placebo in a Phase 2 study. Based on these top-line data from the trial, called PRECEDENT (NCT05318937), Sage will stop any further…
Defects in the VPS13C protein, which have been linked to early-onset Parkinson’s disease, disrupt the function of lysosomes, the cell’s recycling compartments, in dopamine-producing nerve cells that are lost in the neurodegenerative condition. Without functional VPS13C, the Rab10 protein can’t respond properly to lysosomal stress, causing dysfunction in the…
New study findings strengthen scientists’ belief that neuroinflammation — an inflammatory response in the central nervous system — is linked to mood disturbance in people with early Parkinson’s disease. Specifically, elevated levels of pro-inflammatory signaling molecules in the cerebrospinal fluid (CSF) were found to be significantly correlated with worse…
Get regular updates to your inbox.
